CS 585
Alternative Names: CS-585Latest Information Update: 18 Nov 2025
At a glance
- Originator University of Michigan
- Developer Cereno Scientific; University of Michigan
- Class Antiplatelets; Antithrombotics; Cardiovascular therapies; Small molecules
- Mechanism of Action Epoprostenol receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cardiovascular disorders
Most Recent Events
- 10 Nov 2025 CS 585 is still in preclinical trials for Cardiovascular disorders in Sweden (PO)
- 28 May 2025 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Sweden (PO)
- 07 Dec 2024 Pharmacodynamics data from preclinical trials in Cardiovascular disorders presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)